<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.4 20190208//EN"
       "JATS-journalpublishing1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="research-article" dtd-version="1.4" xml:lang="en">
 <front>
  <journal-meta>
   <journal-id journal-id-type="publisher-id">Journal of Natural Sciences Research</journal-id>
   <journal-title-group>
    <journal-title xml:lang="en">Journal of Natural Sciences Research</journal-title>
    <trans-title-group xml:lang="ru">
     <trans-title>Журнал естественнонаучных исследований</trans-title>
    </trans-title-group>
   </journal-title-group>
   <issn publication-format="print">2500-0489</issn>
   <issn publication-format="online">2500-0489</issn>
  </journal-meta>
  <article-meta>
   <article-id pub-id-type="publisher-id">85224</article-id>
   <article-categories>
    <subj-group subj-group-type="toc-heading" xml:lang="ru">
     <subject>Медицинские науки</subject>
    </subj-group>
    <subj-group subj-group-type="toc-heading" xml:lang="en">
     <subject>MEDICINE SCIENCE</subject>
    </subj-group>
    <subj-group>
     <subject>Медицинские науки</subject>
    </subj-group>
   </article-categories>
   <title-group>
    <article-title xml:lang="en">Current state the question of the possibility of increasing the pharmacological activity of peptide drugs</article-title>
    <trans-title-group xml:lang="ru">
     <trans-title>Современное состояние вопроса о возможностях увеличения фармакологической активности пептидных препаратов</trans-title>
    </trans-title-group>
   </title-group>
   <contrib-group content-type="authors">
    <contrib contrib-type="author">
     <name-alternatives>
      <name xml:lang="ru">
       <surname>Смахтина</surname>
       <given-names>А. М.</given-names>
      </name>
      <name xml:lang="en">
       <surname>Smahtina</surname>
       <given-names>A. M.</given-names>
      </name>
     </name-alternatives>
     <xref ref-type="aff" rid="aff-1"/>
    </contrib>
    <contrib contrib-type="author">
     <name-alternatives>
      <name xml:lang="ru">
       <surname>Маль</surname>
       <given-names>Г. С.</given-names>
      </name>
      <name xml:lang="en">
       <surname>Mal</surname>
       <given-names>G. S.</given-names>
      </name>
     </name-alternatives>
     <xref ref-type="aff" rid="aff-1"/>
    </contrib>
    <contrib contrib-type="author">
     <name-alternatives>
      <name xml:lang="ru">
       <surname>Кузнецов</surname>
       <given-names>Д. П.</given-names>
      </name>
      <name xml:lang="en">
       <surname>Kuznecov</surname>
       <given-names>D. P.</given-names>
      </name>
     </name-alternatives>
     <bio xml:lang="ru">
      <p>кандидат философских наук;</p>
     </bio>
     <bio xml:lang="en">
      <p>candidate of philosophical sciences;</p>
     </bio>
     <xref ref-type="aff" rid="aff-1"/>
    </contrib>
   </contrib-group>
   <aff-alternatives id="aff-1">
    <aff>
     <institution xml:lang="ru">Курский государственный медицинский университет</institution>
    </aff>
    <aff>
     <institution xml:lang="en">Kursk State Medical University</institution>
    </aff>
   </aff-alternatives>
   <pub-date publication-format="print" date-type="pub" iso-8601-date="2024-07-09T15:49:24+03:00">
    <day>09</day>
    <month>07</month>
    <year>2024</year>
   </pub-date>
   <pub-date publication-format="electronic" date-type="pub" iso-8601-date="2024-07-09T15:49:24+03:00">
    <day>09</day>
    <month>07</month>
    <year>2024</year>
   </pub-date>
   <volume>9</volume>
   <issue>2</issue>
   <fpage>47</fpage>
   <lpage>51</lpage>
   <history>
    <date date-type="received" iso-8601-date="2024-05-08T00:00:00+03:00">
     <day>08</day>
     <month>05</month>
     <year>2024</year>
    </date>
   </history>
   <self-uri xlink:href="https://naukaru.ru/en/nauka/article/85224/view">https://naukaru.ru/en/nauka/article/85224/view</self-uri>
   <abstract xml:lang="ru">
    <p>С учетом растущего интереса фармацевтической промышленности к пептидным лекарственным средствам были определены современные тенденции развития фармацевтического рынка Российской Федерации. В статье представлены преимущества и недостатки пептидных препаратов, а также особенности их использования в клинической практике. Рассмотрены современные подходы к увеличению фармакологической активности лекарственных средств пептидной природы и результаты исследований, подтверждающих эффективность данных методов.</p>
   </abstract>
   <trans-abstract xml:lang="en">
    <p>Taking into account the growing interest of the pharmaceutical industry in peptide drugs, current trends in the development of the pharmaceutical market in the Russian Federation have been identified. The article presents the advantages and disadvantages of peptide drugs, as well as the features of their use in clinical practice. Modern approaches to increasing the pharmacological activity of peptide drugs and the results of studies confirming the effectiveness of these methods are considered.</p>
   </trans-abstract>
   <kwd-group xml:lang="ru">
    <kwd>пептидные препараты</kwd>
    <kwd>защитные группировки</kwd>
    <kwd>фармакодинамика</kwd>
    <kwd>фармакокинетика</kwd>
    <kwd>модификация пептидной молекулы</kwd>
   </kwd-group>
   <kwd-group xml:lang="en">
    <kwd>peptide drugs</kwd>
    <kwd>protective groups</kwd>
    <kwd>pharmacodynamics</kwd>
    <kwd>pharmacokinetics</kwd>
    <kwd>modification of a peptide molecule</kwd>
   </kwd-group>
  </article-meta>
 </front>
 <body>
  <p></p>
 </body>
 <back>
  <ref-list>
   <ref id="B1">
    <label>1.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Булгаков С.А. Гексапептид даларгин в клинической гастроэнтерологии: 30-летний опыт использования препарата / С.А. Булгаков // Российский журнал гастроэнтерологии, гепатологии, колопроктологии. – 2016. – Т. 26, № 3. – С. 103-112. – DOI: 10.22416/13824376-2016-26-3-103-112.</mixed-citation>
     <mixed-citation xml:lang="en">Bulgakov S.A. Geksapeptid dalargin v klinicheskoy gastroenterologii: 30-letniy opyt ispol'zovaniya preparata / S.A. Bulgakov // Rossiyskiy zhurnal gastroenterologii, gepatologii, koloproktologii. – 2016. – T. 26, № 3. – S. 103-112. – DOI: 10.22416/13824376-2016-26-3-103-112.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B2">
    <label>2.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Жуйкова С.Е. Глипролины — регуляторные пептиды с интегративным действием / С.Е. Жуйкова // Интегративная физиология. – 2020. – Т. 1, № 4. – С. 303–316. – DOI: 10.33910/2687-1270-2020-1-4-303-316.</mixed-citation>
     <mixed-citation xml:lang="en">Zhuykova S.E. Gliproliny — regulyatornye peptidy s integrativnym deystviem / S.E. Zhuykova // Integrativnaya fiziologiya. – 2020. – T. 1, № 4. – S. 303–316. – DOI: 10.33910/2687-1270-2020-1-4-303-316.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B3">
    <label>3.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Исследование фармакокинетики и биодоступности в создании новых оригинальных лекарственных средств пептидной структуры и их оптимальных лекарственных форм / Е.В. Иванникова, В.П. Жердев, С.С. Бойко и др. // Фармакокинетика и фармакодинамика. – 2013. – № 2. – С. 1–17.</mixed-citation>
     <mixed-citation xml:lang="en">Issledovanie farmakokinetiki i biodostupnosti v sozdanii novyh original'nyh lekarstvennyh sredstv peptidnoy struktury i ih optimal'nyh lekarstvennyh form / E.V. Ivannikova, V.P. Zherdev, S.S. Boyko i dr. // Farmakokinetika i farmakodinamika. – 2013. – № 2. – S. 1–17.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B4">
    <label>4.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Полянский М.А. Основные концепции синтеза пептидов как нового поколения биологически активных препаратов / М.А. Полянский, А.И. Гинак // Известия CанктПетербургского государственного технологического института (технического университета). – 2021. – № 58 (84). – С. 62–65.</mixed-citation>
     <mixed-citation xml:lang="en">Polyanskiy M.A. Osnovnye koncepcii sinteza peptidov kak novogo pokoleniya biologicheski aktivnyh preparatov / M.A. Polyanskiy, A.I. Ginak // Izvestiya CanktPeterburgskogo gosudarstvennogo tehnologicheskogo instituta (tehnicheskogo universiteta). – 2021. – № 58 (84). – S. 62–65.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B5">
    <label>5.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Сломинский, П.А. Пептидные лекарственные средства: возможности, перспективы и ограничения / П.А. Сломинский, М.И. Шадрина // Молекулярная генетика, микробиология и вирусология. – 2018. – Т. 36, № 1. – С. 8–14. – DOI: 10.18821/0208-06132018-36-1-8-14.</mixed-citation>
     <mixed-citation xml:lang="en">Slominskiy, P.A. Peptidnye lekarstvennye sredstva: vozmozhnosti, perspektivy i ogranicheniya / P.A. Slominskiy, M.I. Shadrina // Molekulyarnaya genetika, mikrobiologiya i virusologiya. – 2018. – T. 36, № 1. – S. 8–14. – DOI: 10.18821/0208-06132018-36-1-8-14.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B6">
    <label>6.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Хавинсон В.Х. Лекарственные пептидные препараты: прошлое, настоящее, будущее / В.Х. Хавинсон // Клиническая медицина. – 2020. – № 98 (3). – С. 165–177. – DOI:10.30629/0023-2149-2020-98-3-165-177.</mixed-citation>
     <mixed-citation xml:lang="en">Havinson V.H. Lekarstvennye peptidnye preparaty: proshloe, nastoyaschee, buduschee / V.H. Havinson // Klinicheskaya medicina. – 2020. – № 98 (3). – S. 165–177. – DOI:10.30629/0023-2149-2020-98-3-165-177.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B7">
    <label>7.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">An assessment tumor targeting ability of (177)Lu labeled cyclic CCK analogue peptide by binding with cholecystokinin receptor / E.H. Cho, J.C. Lim, S.Y. Lee, S.H. Jung // Journal of Pharmacological Sciences. – 2016. – № 131 (3). – P. 209–214. – DOI: 10.1016/j.jphs.2016.06.006.</mixed-citation>
     <mixed-citation xml:lang="en">An assessment tumor targeting ability of (177)Lu labeled cyclic CCK analogue peptide by binding with cholecystokinin receptor / E.H. Cho, J.C. Lim, S.Y. Lee, S.H. Jung // Journal of Pharmacological Sciences. – 2016. – № 131 (3). – P. 209–214. – DOI: 10.1016/j.jphs.2016.06.006.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B8">
    <label>8.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">A review on the strategies for oral delivery of proteins and peptides and their clinical perspectives / A. Muheem, F. Shakeel, M.A. Jahangir, M. Anwar et al. // Saudi Pharmaceutical Journal. – 2016. – № 24 (4). – P. 413–428. – DOI: 10.1016/j.jsps.2014.06.004.</mixed-citation>
     <mixed-citation xml:lang="en">A review on the strategies for oral delivery of proteins and peptides and their clinical perspectives / A. Muheem, F. Shakeel, M.A. Jahangir, M. Anwar et al. // Saudi Pharmaceutical Journal. – 2016. – № 24 (4). – P. 413–428. – DOI: 10.1016/j.jsps.2014.06.004.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B9">
    <label>9.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Development and testing of solid dose formulations containing polysialic acid insulin conjugate: next generation of long-acting insulin / R. Zhang, S. Jain, M. Rowland et al. // Journal of Diabetes Science and Technology. – 2010. – № 4 (3). – P. 532–539. – DOI: 10.1177/193229681000400305.</mixed-citation>
     <mixed-citation xml:lang="en">Development and testing of solid dose formulations containing polysialic acid insulin conjugate: next generation of long-acting insulin / R. Zhang, S. Jain, M. Rowland et al. // Journal of Diabetes Science and Technology. – 2010. – № 4 (3). – P. 532–539. – DOI: 10.1177/193229681000400305.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B10">
    <label>10.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Development of peptide Biopharmaceuticals in Russia / V.I. Deigin, E.A. Poluektova, A.G. Beniashvili et al. // Pharmaceutics. – 2022. – № 14 (4). – P. 716. – DOI:10.3390/pharmaceutics14040716.</mixed-citation>
     <mixed-citation xml:lang="en">Development of peptide Biopharmaceuticals in Russia / V.I. Deigin, E.A. Poluektova, A.G. Beniashvili et al. // Pharmaceutics. – 2022. – № 14 (4). – P. 716. – DOI:10.3390/pharmaceutics14040716.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B11">
    <label>11.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Diao L. Pharmacokinetics and pharmacokinetic-pharmacodynamic correlations of therapeutic peptides / L. Diao, B. Meibohm // Clinical Pharmacokinetics. – 2013. – № 52 (10). – P. 855–868. – DOI: 10.1007/s40262-013-0079-0.</mixed-citation>
     <mixed-citation xml:lang="en">Diao L. Pharmacokinetics and pharmacokinetic-pharmacodynamic correlations of therapeutic peptides / L. Diao, B. Meibohm // Clinical Pharmacokinetics. – 2013. – № 52 (10). – P. 855–868. – DOI: 10.1007/s40262-013-0079-0.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B12">
    <label>12.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Evaluation of Neuroprotective and Adjuvant Activities of Diketopiperazine-Based Peptidomimetics / V. Deigin, M. Premyslova, O. Ksenofontova et al. // Chemistry Select. 2023. – V. 8, № 8. – e202204076. – DOI:10.1002/slct.202204076.</mixed-citation>
     <mixed-citation xml:lang="en">Evaluation of Neuroprotective and Adjuvant Activities of Diketopiperazine-Based Peptidomimetics / V. Deigin, M. Premyslova, O. Ksenofontova et al. // Chemistry Select. 2023. – V. 8, № 8. – e202204076. – DOI:10.1002/slct.202204076.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B13">
    <label>13.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Glu-Trp-ONa or its acylated analogue (R-Glu-Trp-ONa) administration enhances the wound healing in the model of chronic skin wounds in rabbits / M.A. Shevtsov, L.V. Smagina, T.A. Kudriavtceva et al. // Drug design, development and therapy. – 2015. – № 9. – P. 1717–1727. – DOI: 10.2147/DDDT.S79665.</mixed-citation>
     <mixed-citation xml:lang="en">Glu-Trp-ONa or its acylated analogue (R-Glu-Trp-ONa) administration enhances the wound healing in the model of chronic skin wounds in rabbits / M.A. Shevtsov, L.V. Smagina, T.A. Kudriavtceva et al. // Drug design, development and therapy. – 2015. – № 9. – P. 1717–1727. – DOI: 10.2147/DDDT.S79665.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B14">
    <label>14.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Greening the synthesis of peptide therapeutics: an industrial perspective / V. Martin, P.H.G.Egelund, H. Johansson et al. // RSC Advances. – 2020. – № 10 (69). – P. 42457–42492. – DOI: 10.1039/d0ra07204d.</mixed-citation>
     <mixed-citation xml:lang="en">Greening the synthesis of peptide therapeutics: an industrial perspective / V. Martin, P.H.G.Egelund, H. Johansson et al. // RSC Advances. – 2020. – № 10 (69). – P. 42457–42492. – DOI: 10.1039/d0ra07204d.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B15">
    <label>15.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Introduction of D-Phenylalanine enhanced the receptor binding affinities of gonadotropinreleasing hormone peptides / J. Lu, H.J. Hathaway, M.E. Royce et al. // Bioorganic &amp; Medicinal Chemistry Letters. – 2014. – № 24. – P. 725–730. – DOI: 10.1016/j.bmcl.2013.12.120.</mixed-citation>
     <mixed-citation xml:lang="en">Introduction of D-Phenylalanine enhanced the receptor binding affinities of gonadotropinreleasing hormone peptides / J. Lu, H.J. Hathaway, M.E. Royce et al. // Bioorganic &amp; Medicinal Chemistry Letters. – 2014. – № 24. – P. 725–730. – DOI: 10.1016/j.bmcl.2013.12.120.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B16">
    <label>16.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Neuroprotective Peptides and New Strategies for Ischemic Stroke Drug Discoveries / L.V. Dergunova, I.B. Filippenkov, S.A. Limborska, N.F. Myasoedov // Genes. – 2023. – № 14. – P.953. – DOI: 10.3390/genes14050953.</mixed-citation>
     <mixed-citation xml:lang="en">Neuroprotective Peptides and New Strategies for Ischemic Stroke Drug Discoveries / L.V. Dergunova, I.B. Filippenkov, S.A. Limborska, N.F. Myasoedov // Genes. – 2023. – № 14. – P.953. – DOI: 10.3390/genes14050953.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B17">
    <label>17.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Population pharmacokinetics of cyclosporine A in Japanese renal transplant patients: comprehensive analysis in a single center / A. Okada, Ushigome, M. Kanamori et al. // European Journal of Clinical Pharmacology. – 2017. – № 73 (9). – P. 1111–1119. – DOI: 10.1007/s00228-017-2279-2.</mixed-citation>
     <mixed-citation xml:lang="en">Population pharmacokinetics of cyclosporine A in Japanese renal transplant patients: comprehensive analysis in a single center / A. Okada, Ushigome, M. Kanamori et al. // European Journal of Clinical Pharmacology. – 2017. – № 73 (9). – P. 1111–1119. – DOI: 10.1007/s00228-017-2279-2.</mixed-citation>
    </citation-alternatives>
   </ref>
  </ref-list>
 </back>
</article>
